BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 37114512)

  • 1. Bleeding events associated with recombinant human soluble thrombomodulin, classified according to renal function, in sepsis-induced disseminated intravascular coagulation.
    Onoda T; Aoyama K; Suzuki M; Matsumoto T; Tanaka H; Ishii T
    Int J Clin Pharmacol Ther; 2023 Jul; 61(7):297-305. PubMed ID: 37114512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of recombinant human soluble thrombomodulin in patients with sepsis-induced disseminated intravascular coagulation - A meta-analysis.
    Kato H; Hagihara M; Asai N; Umemura T; Hirai J; Mori N; Yamagishi Y; Iwamoto T; Mikamo H
    Thromb Res; 2023 Jun; 226():165-172. PubMed ID: 37182388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effective control of relapsing disseminated intravascular coagulation in a patient with decompensated liver cirrhosis by recombinant soluble thrombomodulin.
    Hasebe T; Sawada K; Nakajima S; Maeda S; Abe M; Suzuki Y; Ohtake T; Hasebe C; Fujiya M; Kohgo Y
    Intern Med; 2014; 53(1):29-33. PubMed ID: 24390524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysis.
    Yamakawa K; Ogura H; Fujimi S; Morikawa M; Ogawa Y; Mohri T; Nakamori Y; Inoue Y; Kuwagata Y; Tanaka H; Hamasaki T; Shimazu T
    Intensive Care Med; 2013 Apr; 39(4):644-52. PubMed ID: 23361628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Recombinant Human Soluble Thrombomodulin on Coagulation-Related Variables in Patients With Sepsis-Induced Disseminated Intravascular Coagulation: A Retrospective Observational Study.
    Mitaka C; Kawagoe I; Satoh D; Hayashida M
    Clin Appl Thromb Hemost; 2021; 27():10760296211050356. PubMed ID: 34859680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant human soluble thrombomodulin and mortality in sepsis-induced disseminated intravascular coagulation. A multicentre retrospective study.
    Hayakawa M; Yamakawa K; Saito S; Uchino S; Kudo D; Iizuka Y; Sanui M; Takimoto K; Mayumi T; Ono K;
    Thromb Haemost; 2016 Jun; 115(6):1157-66. PubMed ID: 26939575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multicenter clinical experience with recombinant soluble thrombomodulin for disseminated intravascular coagulation associated with severe acute cholecystitis.
    Ogura T; Eguchi T; Amano M; Sano T; Nishioka N; Miyano A; Tsujimae M; Tanimura H; Yamada T; Terashima Y; Okada A; Higuchi K
    Thromb Res; 2019 Apr; 176():74-78. PubMed ID: 30780007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant human soluble thrombomodulin in severe sepsis: a systematic review and meta-analysis.
    Yamakawa K; Aihara M; Ogura H; Yuhara H; Hamasaki T; Shimazu T
    J Thromb Haemost; 2015 Apr; 13(4):508-19. PubMed ID: 25581687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of recombinant human thrombomodulin and gabexate mesylate for treatment of disseminated intravascular coagulation (DIC) with sepsis following emergent gastrointestinal surgery: a retrospective study.
    Akahoshi T; Sugimori H; Kaku N; Tokuda K; Nagata T; Noda E; Morita M; Hashizume M; Maehara Y
    Eur J Trauma Emerg Surg; 2015 Oct; 41(5):531-8. PubMed ID: 26038004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A retrospective comparative study of recombinant human thrombomodulin and gabexate mesilate in sepsis-induced disseminated intravascular coagulation patients.
    Takazono T; Nakamura S; Imamura Y; Yoshioka S; Miyazaki T; Izumikawa K; Sawai T; Matsuo N; Yanagihara K; Suyama N; Kohno S
    J Infect Chemother; 2014 Aug; 20(8):484-8. PubMed ID: 24855912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy and safety of antithrombin and recombinant human thrombomodulin combination therapy in patients with severe sepsis and disseminated intravascular coagulation.
    Yasuda N; Goto K; Ohchi Y; Abe T; Koga H; Kitano T
    J Crit Care; 2016 Dec; 36():29-34. PubMed ID: 27546744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, double-blind, placebo-controlled, Phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation.
    Vincent JL; Ramesh MK; Ernest D; LaRosa SP; Pachl J; Aikawa N; Hoste E; Levy H; Hirman J; Levi M; Daga M; Kutsogiannis DJ; Crowther M; Bernard GR; Devriendt J; Puigserver JV; Blanzaco DU; Esmon CT; Parrillo JE; Guzzi L; Henderson SJ; Pothirat C; Mehta P; Fareed J; Talwar D; Tsuruta K; Gorelick KJ; Osawa Y; Kaul I
    Crit Care Med; 2013 Sep; 41(9):2069-79. PubMed ID: 23979365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of recombinant human soluble thrombomodulin on disseminated intravascular coagulation in an abdominal aortic aneurysm.
    Hoshina K; Shigematsu K; Hosaka A; Okamoto H; Miyata T; Watanabe T
    Blood Coagul Fibrinolysis; 2014 Jun; 25(4):389-91. PubMed ID: 24378974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors Determining the Efficacy of Recombinant Human Thrombomodulin in the Treatment of Sepsis-Induced Disseminated Intravascular Coagulation.
    Kotake K; Hongo T; Tahira A; Niimi N; Haisa I; Kawakami Y
    Biol Pharm Bull; 2021 May; 44(5):605-610. PubMed ID: 33612566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination effect of antithrombin and recombinant human soluble thrombomodulin in a lipopolysaccharide induced rat sepsis model.
    Iba T; Nakarai E; Takayama T; Nakajima K; Sasaoka T; Ohno Y
    Crit Care; 2009; 13(6):R203. PubMed ID: 20003418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical impact of recombinant thrombomodulin administration on disseminated intravascular coagulation due to severe acute cholangitis (Recover-AC study).
    Ogura T; Eguchi T; Nakahara K; Kanno Y; Omoto S; Itonaga M; Kuroda T; Hakoda A; Ikeoka S; Takagi M; Okada A; Sato J; Morita R; Michikawa Y; Ito K; Koshita S; Takenaka M; Kitano M; Koizumi M; Higuchi K
    J Hepatobiliary Pancreat Sci; 2023 Feb; 30(2):221-228. PubMed ID: 34021720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of recombinant human soluble thrombomodulin in patients with sepsis-associated coagulopathy: A systematic review and meta-analysis.
    Valeriani E; Squizzato A; Gallo A; Porreca E; Vincent JL; Iba T; Hagiwara A; Di Nisio M
    J Thromb Haemost; 2020 Jul; 18(7):1618-1625. PubMed ID: 32237269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antithrombin supplementation and risk of bleeding in patients with sepsis-associated disseminated intravascular coagulation.
    Iba T; Gando S; Saitoh D; Wada H; Di Nisio M; Thachil J
    Thromb Res; 2016 Sep; 145():46-50. PubMed ID: 27479532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy of recombinant human soluble thrombomodulin for obstetric disseminated intravascular coagulation: a retrospective study.
    Yoshihara M; Uno K; Tano S; Mayama M; Ukai M; Kondo S; Kokabu T; Kishigami Y; Oguchi H
    Crit Care; 2015 Oct; 19():369. PubMed ID: 26481315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and bleeding risk of antithrombin supplementation in septic disseminated intravascular coagulation: a secondary survey.
    Iba T; Saitoh D; Wada H; Asakura H
    Crit Care; 2014 Sep; 18(5):497. PubMed ID: 25220851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.